Evidence map›Paper›PMID 40963902›Full record

ArticleTheranostics2025

RIPK3 promotes ASIC1a-mediated fibroblast-like synoviocyte migration and invasion via malate shuttle-driven mitochondrial respiration in rheumatoid arthritis.

Weirong Hu, Ke Wang, Yalu Dong, Yucai Xu, Jing Xing, Jianzhong Zhu, Jie Ding, Yingjie Zhao, Yayun Xu, Yuanzhi Cheng and 4 more

Abstract read
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Weirong HuSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Ke WangDepartment of Clinical Pharmacology, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Yalu DongSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Yucai XuSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Jing XingSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Jianzhong ZhuSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Jie DingDepartment of Clinical Pharmacology, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Yingjie ZhaoDepartment of Clinical Pharmacology, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Yayun XuShenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, China.
Yuanzhi ChengDepartment of Clinical Pharmacology, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Xiaoqing PengSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Renpeng ZhouSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.
Wei HuDepartment of Clinical Pharmacology, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Feihu ChenSchool of Pharmacy; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acid Sensing Ion ChannelsArthritis, RheumatoidMalatesMitochondriaReceptor-Interacting Protein Serine-Threonine KinasesSynoviocytesAnimalsCell MovementFemaleFibroblastsHumansMaleMiceMice, Inbred C57BLMice, KnockoutAcid Sensing Ion ChannelsASIC1 protein, humanMalatesReceptor-Interacting Protein Serine-Threonine KinasesASIC1afibroblast-like synoviocytemalate shuttlerheumatoid arthritisRIPK3

Identifiers

PMID40963902
PMCPMC12439152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.